Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma

Internal Medicine Journal
Judith TrotmanStephen Opat

Abstract

Outcomes with follicular lymphoma (FL) have improved in the modern era and median survival is now beyond 15 years. Therapeutic decisions need to consider this increased survival as well as recent clinical trial data and emerging treatments. In this context, we present here current approaches to front-line management of FL in Australia. Treatment choices depend on the disease stage, tumour burden, the patient's age, symptoms, comorbidities and preferences. Only about 10-15% of patients with FL are diagnosed with early stage disease. For patients with low-grade, early stage disease, radiotherapy (RT) is recommended. The addition of chemotherapy has been shown to increase progression-free survival (PFS) but without demonstrated overall survival advantage. For patients with low-tumour-burden, advanced-stage FL, immediate treatment may not be required and we recommend considering active monitoring. For stage III/IV disease that is symptomatic and/or with high tumour burden, established first-line treatment is chemotherapy in combination with rituximab, often followed by rituximab maintenance. The listing of bendamustine and now obinutuzumab on the Pharmaceutical Benefits Scheme has expanded the first-line treatment options in Austra...Continue Reading

References

Mar 26, 2003·Seminars in Oncology·Wolfgang HiddemannMichael Unterhalt
Jul 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert MarcusGeorge Stein
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoPhilippe Solal-Céligny
Sep 9, 2010·Urologic Oncology·Arshad A PandithMushtaq A Siddiqi
Aug 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan W FriedbergThomas P Miller
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoMaura Brugiatelli
May 7, 2013·Haematologica·Emmanuel BachyUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Jan 5, 2014·Journal of Clinical Pharmacy and Therapeutics·S LimatE Deconinck
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahN H Fowler
Mar 19, 2016·Blood·Brad S Kahl, David T Yang
Jun 15, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clémentine SarkozyHervé Tilly
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingUNKNOWN ESMO Guidelines Committee
Feb 1, 2003·Seminars in Oncology·UNKNOWN German Low Grade Lymphoma Study GroupMichael Unterhalt
Mar 25, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Liat VidalOfer Shpilberg
May 12, 2017·PloS One·Mariano ProvencioUNKNOWN GOTEL (Spanish Lymphoma Oncology Group)
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Nov 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefano LuminariMassimo Federico
Jun 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang HiddemannRobert E Marcus

❮ Previous
Next ❯

Citations

Oct 12, 2019·Internal Medicine Journal·Judith TrotmanStephen Opat
Sep 2, 2020·Expert Review of Hematology·Emanuele CenciniMonica Bocchia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.